Building high-resolution synthetic lethal networks: a 'Google map' of the cancer cell.
暂无分享,去创建一个
F. Vizeacoumar | A. Freywald | Franco J Vizeacoumar | Andrew Freywald | Akanksha Baharani | Akanksha Baharani | James M Paul | Shaina D Templeton | Shaina D. Templeton | James M. Paul
[1] Yilong Li,et al. Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library , 2013, Nature Biotechnology.
[2] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[3] Yiyu Dong,et al. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.
[4] K. McManus,et al. Synthetic Genetic Targeting of Genome Instability in Cancer , 2013, Cancers.
[5] Xiangwei Wu,et al. An intermittent approach for cancer chemoprevention , 2011, Nature Reviews Cancer.
[6] A. Krasnitz,et al. An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer , 2008, Cell.
[7] Brady Bernard,et al. Synthetic lethal screens as a means to understand and treat MYC-driven cancers. , 2014, Cold Spring Harbor perspectives in medicine.
[8] Roland Arnold,et al. A negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilities , 2013, Molecular systems biology.
[9] C. Chuong,et al. SnapShot: Branching Morphogenesis , 2014, Cell.
[10] Wolfgang Huber,et al. Mapping of signaling networks through synthetic genetic interaction analysis by RNAi , 2011, Nature Methods.
[11] M. Yaffe,et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. , 2013, Cell reports.
[12] Nevan J Krogan,et al. High-throughput genetic interaction mapping in the fission yeast Schizosaccharomyces pombe , 2007, Nature Methods.
[13] P. Hieter,et al. Saccharomyces cerevisiae Genetics Predicts Candidate Therapeutic Genetic Interactions at the Mammalian Replication Fork , 2013, G3: Genes | Genomes | Genetics.
[14] Gary D Bader,et al. The Genetic Landscape of a Cell , 2010, Science.
[15] R. Barrangou,et al. CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes , 2007, Science.
[16] Joshua M. Stuart,et al. A global analysis of genetic interactions in Caenorhabditis elegans , 2007, Journal of biology.
[17] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[18] C. Grandori. A high-throughput siRNA screening platform to identify MYC-synthetic lethal genes as candidate therapeutic targets. , 2013, Methods in molecular biology.
[19] Lucas Pelkmans,et al. A Hierarchical Map of Regulatory Genetic Interactions in Membrane Trafficking , 2014, Cell.
[20] A. Giaccia,et al. Harnessing synthetic lethal interactions in anticancer drug discovery , 2011, Nature Reviews Drug Discovery.
[21] Jacques Colinge,et al. A chemical genetic screen reveals a resistance mechanism to PI3K inhibitors in cancer , 2011, Nature chemical biology.
[22] M. Barbacid,et al. RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.
[23] Kevin R Brown,et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. , 2012, Cancer discovery.
[24] T. Eberlein,et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation , 2012 .
[25] A. Rose,et al. Synthetic Lethal Interactions Identify Phenotypic “Interologs” of the Spindle Assembly Checkpoint Components , 2007, Genetics.
[26] S. Magdaleno,et al. Discovery of a Dicer-Independent, Cell-Type Dependent Alternate Targeting Sequence Generator: Implications in Gene Silencing & Pooled RNAi Screens , 2014, PloS one.
[27] Ian Collins,et al. New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.
[28] Patrick J. Paddison,et al. A resource for large-scale RNA-interference-based screens in mammals , 2004, Nature.
[29] D. Durocher,et al. Significant conservation of synthetic lethal genetic interaction networks between distantly related eukaryotes , 2008, Proceedings of the National Academy of Sciences.
[30] K. Kinzler,et al. Cancer Genome Landscapes , 2013, Science.
[31] Hiroshi Nishimasu. Crystal Structure of Cas9 , 2015 .
[32] F. Zhang,et al. CRISPR/Cas9 for genome editing: progress, implications and challenges. , 2014, Human molecular genetics.
[33] Andreas Schlicker,et al. Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. , 2014, Cell reports.
[34] Yolanda T. Chong,et al. A picture is worth a thousand words: Genomics to phenomics in the yeast Saccharomyces cerevisiae , 2009, FEBS letters.
[35] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[36] P. Hieter,et al. Establishing genetic interactions by a synthetic dosage lethality phenotype. , 1996, Genetics.
[37] Aaron N. Chang,et al. Functional genomics identifies therapeutic targets for MYC-driven cancer , 2012, Proceedings of the National Academy of Sciences.
[38] Alan Ashworth,et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. , 2014, Cancer research.
[39] P. Hieter,et al. Synthetic Lethal Targeting of Superoxide Dismutase 1 Selectively Kills RAD54B-Deficient Colorectal Cancer Cells , 2013, Genetics.
[40] P. Hieter,et al. An Evolutionarily Conserved Synthetic Lethal Interaction Network Identifies FEN1 as a Broad-Spectrum Target for Anticancer Therapeutic Development , 2013, PLoS genetics.
[41] Wolfgang Huber,et al. Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping , 2013, Nature Methods.
[42] Jef D Boeke,et al. dSLAM analysis of genome-wide genetic interactions in Saccharomyces cerevisiae. , 2007, Methods.
[43] F. Ciccarelli,et al. Recessive cancer genes engage in negative genetic interactions with their functional paralogs. , 2013, Cell reports.
[44] Anne E Carpenter,et al. A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen , 2006, Cell.
[45] Nathan T. Ross,et al. A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells , 2012, ACS medicinal chemistry letters.
[46] Nathan T. Ross,et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability , 2012, Proceedings of the National Academy of Sciences.
[47] Jeff Piotrowski,et al. A comparative genomic approach for identifying synthetic lethal interactions in human cancer. , 2013, Cancer research.
[48] Stephen H. Friend,et al. Potential of the Synthetic Lethality Principle , 2013, Science.
[49] P Manimaran,et al. Identification of synthetic lethal pairs in biological systems through network information centrality. , 2013, Molecular bioSystems.
[50] P. Reaper,et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. , 2011, Nature chemical biology.
[51] J. C. Love,et al. In vivo discovery of immunotherapy targets in the tumour microenvironment , 2014, Nature.
[52] L. Zender,et al. Deregulated MYC expression induces dependence upon AMPK-related kinase 5 , 2012, Nature.
[53] Lyndsay N Harris,et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] A. Sparks,et al. The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.
[55] E. Lander,et al. Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.
[56] A. Gown,et al. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.
[57] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[58] Grant W. Brown,et al. Chemical–Genetic Profiling of Imidazo[1,2-a]pyridines and -Pyrimidines Reveals Target Pathways Conserved between Yeast and Human Cells , 2008, PLoS genetics.
[59] J. McCarter,et al. STK33 kinase activity is nonessential in KRAS-dependent cancer cells. , 2011, Cancer research.
[60] Ji Luo,et al. A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis , 2012, Science.
[61] J. Settleman,et al. Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.
[62] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[63] Richard Simon,et al. Identification of potential synthetic lethal genes to p53 using a computational biology approach , 2013, BMC Medical Genomics.
[64] T. Eguchi,et al. RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene , 2007, Oncogene.
[65] Sridhar Ramaswamy,et al. Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells , 2009, Cell.
[66] Ben Lehner,et al. Evolutionary plasticity of genetic interaction networks , 2008, Nature Genetics.
[67] Curt I Civin,et al. Personalized synthetic lethality induced by targeting RAD52 in leukemias identified by gene mutation and expression profile. , 2013, Blood.
[68] B. Andrews,et al. Systematic mapping of genetic interaction networks. , 2009, Annual review of genetics.
[69] M. Piccart,et al. First-Line Treatment of Metastatic Breast Cancer , 2006 .
[70] I. Mellinghoff,et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer , 2006, Nature Medicine.
[71] C. Grandori,et al. Functional genomics to identify unforeseen cancer drug targets. , 2013, Future oncology.
[72] P. Hieter,et al. Synthetic lethal genetic interactions that decrease somatic cell proliferation in Caenorhabditis elegans identify the alternative RFC CTF18 as a candidate cancer drug target. , 2009, Molecular biology of the cell.
[73] Malini Guha. PARP inhibitors stumble in breast cancer , 2011, Nature Biotechnology.
[74] Reuven Agami,et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway , 2004, Nature.
[75] Hong Liu,et al. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.
[76] Frederick S. Vizeacoumar,et al. Systematic exploration of essential yeast gene function with temperature-sensitive mutants , 2011, Nature Biotechnology.
[77] Yang Bian,et al. Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors , 2014, Proceedings of the National Academy of Sciences.
[78] Hong Wu,et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[79] Franco J. Vizeacoumar,et al. Integrating high-throughput genetic interaction mapping and high-content screening to explore yeast spindle morphogenesis , 2010, The Journal of cell biology.
[80] Sourav Bandyopadhyay,et al. Quantitative genetic-interaction mapping in mammalian cells , 2013, Nature Methods.
[81] C. Kemp,et al. Synthetic lethality between mutation in Atm and DNA-PKcs during murine embryogenesis , 2001, Current Biology.
[82] Bhavneet Bhinder,et al. Systematic analysis of RNAi reports identifies dismal commonality at gene-level and reveals an unprecedented enrichment in pooled shRNA screens. , 2013, Combinatorial chemistry & high throughput screening.
[83] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2007, Nature.
[84] Eytan Ruppin,et al. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.
[85] B. Druker,et al. Applying the discovery of the Philadelphia chromosome. , 2007, The Journal of clinical investigation.
[86] J. Blenis,et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[87] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[88] Michael T. McManus,et al. A Systematic Mammalian Genetic Interaction Map Reveals Pathways Underlying Ricin Susceptibility , 2013, Cell.
[89] C. Roberts,et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers , 2014, Proceedings of the National Academy of Sciences.
[90] L. Hartwell,et al. Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.
[91] Grant W. Brown,et al. Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map , 2007, Nature.
[92] René Bernards,et al. A Missing Link in Genotype-Directed Cancer Therapy , 2012, Cell.
[93] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[94] P. Hieter,et al. Specific synthetic lethal killing of RAD54B-deficient human colorectal cancer cells by FEN1 silencing , 2009, Proceedings of the National Academy of Sciences.
[95] Anna Marie Mulligan,et al. JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer , 2008, Breast Cancer Research and Treatment.
[96] Michael J. Emanuele,et al. A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene , 2009, Cell.